WILMINGTON, Del. — Global biopharmaceutical giant AstraZeneca announced plans on Monday to invest $50 billion in the United States by 2030, marking the company’s largest-ever financial commitment to a single country.
The sweeping investment strategy aims to strengthen the U.S. role in global medicines manufacturing and research and development (R&D), while helping AstraZeneca reach its ambitious revenue target of $80 billion by the end of the decade — with half of that expected to come from the U.S. market.
At the heart of the plan is a proposed multi-billion dollar drug substance manufacturing facility in the Commonwealth of Virginia. The state-of-the-art site would be AstraZeneca’s largest single manufacturing investment globally, focusing on chronic disease treatments, including its growing weight management and metabolic portfolio. These include next-generation oral GLP-1s, baxdrostat, oral PCSK9s, and small molecule combination therapies. The facility will harness AI, automation, and advanced data analytics to streamline production of small molecules, peptides, and oligonucleotides.
“This historic investment is bringing tens of thousands of jobs to the U.S. and will ensure medicine sold in our country is produced right here,” said U.S. Secretary of Commerce Howard Lutnick. “President Trump and our nation’s new tariff policies are focused on ending our reliance on foreign pharmaceutical supply chains.”
Virginia Governor Glenn Youngkin celebrated the company’s decision to place its flagship project in his state, calling it “transformational.”
“This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation’s domestic supply chain,” said Youngkin. “I am thrilled that AstraZeneca, one of the world’s leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.”
In addition to the Virginia facility, AstraZeneca’s investment plan includes:
-
Expansion of its R&D campus in Gaithersburg, Maryland
-
A new research center in Kendall Square, Cambridge, Massachusetts
-
Advanced manufacturing sites for cell therapy in Rockville, Maryland, and Tarzana, California
-
Continuous manufacturing upgrades in Mount Vernon, Indiana
-
Specialty production enhancements in Coppell, Texas
-
New clinical trial supply sites across the country
The company says these projects will create tens of thousands of direct and indirect jobs while advancing U.S. leadership in pharmaceutical innovation and strengthening the country’s domestic medicine supply.
“Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally,” said Pascal Soriot, Chief Executive Officer of AstraZeneca. “It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines.”
